儿童孤独症谱系障碍的治疗研究进展

李洪华; 单玲; 杜琳; 贾飞勇

doi:10.7499/j.issn.1008-8830.2015.08.026

PDF(1717 KB)

HTML

中国当代儿科杂志 ›› 2015, Vol. 17 ›› Issue (8) : 886-892. DOI: 10.7499/j.issn.1008-8830.2015.08.026

综述

儿童孤独症谱系障碍的治疗研究进展

李洪华, 单玲, 杜琳, 贾飞勇

作者信息 +

Research advances in the management of autism spectrum disorders in children

LI Hong-Hua, SHAN Ling, DU Lin, JIA Fei-Yong

Author information +

文章历史 +

摘要

孤独症谱系障碍(ASD)为一类广泛性神经系统发育障碍,以社会交往及交流障碍、兴趣狭窄、刻板与重复行为为主要特点。目前ASD的发病率呈显著上升趋势,早期合理的个性化综合干预治疗可明显改善患儿预后。由于ASD的病因不明,目前尚无特效药,主要以行为与教育干预为主;对ASD的伴发症状,如易激惹、自伤行为、注意缺陷多动障碍、睡眠问题等,合理应用一些药物,可改善ASD患儿的行为干预效果。随着ASD发病机制的深入研究,布美他尼、催产素、维生素D及高压氧治疗,可有望改善ASD核心症状。该文对目前针对ASD的行为与发展干预及治疗方法进行了综述。

Abstract

Autism spectrum disorders (ASD) are a group of developmental dysfuntion of nervous system characterized by social interaction and communication disorders, restricted interests and repetitive stereotyped behaviors. The incidence of ASD has been increasing through the world. Some studies have shown that early reasonable individualized comprehensive intervention can obviously improve the prognosis of children with ASD. The etiology of ASD is unclear now, and behavioral and developmental intervention is the main therapy for ASD. The reasonable application of some drugs can improve the efficacy of the behavioral intervention for concomitant symptoms in ASD. With the in-depth study of the pathogenesis of ASD, bumetanide, oxytocin, vitamin D and hyperbaric oxygen therapy have been found to be promising for the improvement of core symptoms of ASD. This article reviews the research advances in the behavioral and developmental intervention and drug therapy for ASD.

导出引用

李洪华, 单玲, 杜琳, 贾飞勇. 儿童孤独症谱系障碍的治疗研究进展[J]. 中国当代儿科杂志. 2015, 17(8): 886-892 https://doi.org/10.7499/j.issn.1008-8830.2015.08.026

LI Hong-Hua, SHAN Ling, DU Lin, JIA Fei-Yong. Research advances in the management of autism spectrum disorders in children[J]. Chinese Journal of Contemporary Pediatrics. 2015, 17(8): 886-892 https://doi.org/10.7499/j.issn.1008-8830.2015.08.026

参考文献

[1] Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 sites, United States, 2010[J]. MMWR Surveill Summ, 2014, 63(2): 1-21.
[2] Gutstein SE. Empowering families through relationship development intervention: an important part of the biopsychosocial management of autism spectrum disorders[J]. Ann Clin Psychiatry, 2009, 21(3): 174-182.
[3] Lal R, Bali M. Effect of visual strategies on development of communication skills in children with autism[J]. Asia Pacific Dis Rehabilit J, 2007, 18(2):120-130.
[4] Maglione MA, Gans D, Das L, et al. Nonmedical interventions for children with ASD: recommended guidelines and further research needs[J]. Pediatrics, 2012, 130(Suppl 2): S169-S178.
[5] Warren Z, McPheeters ML, Sathe N, et al. A systematicreview of early intensive intervention for autism spectrum disorders[J]. Pediatrics, 2011, 127(5): 1303-1311.
[6] Rogers S, Dawson G. Early start denver model for young children with autism: promoting language, learning, and engagement[M]. New York: The Guilford Press, 2009: 77-78.
[7] Fulton E, Eapen V, Crncec R, et al. Reducing maladaptive behaviors in preschool-aged children with autism spectrum disorder using the early startdenver model[J]. Front Pediatr, 2014, 9(2): 40.
[8] Vivanti G, Paynter J, Duncan E, et al. Effectiveness and feasibility of the early start denver model implemented in a group-based community childcare setting[J]. J Autism Dev Disord, 2014, 44(12): 3140-3153.
[9] Dawson G, Jones EJ, Merkle K, et al. Early behavioral intervention is associated with normalized brain activity in young children with autism[J]. J Am Acad Child Adolesc Psychiatry, 2012, 51(11): 1150-1159.
[10] Rogers SJ, Estes A, Lord C, et al. Effects of a brief early start denver model(ESDM)-based parent intervention on toddlers at risk for autism spectrum disorders: a randomized controlled trial[J]. J Am Acad Child Adolesc Psychiatry, 2012, 51(10): 1052-1065.
[11] Eapen V, Crncec R, Walter A. Clinical outcomes of early intervention program for preschool children with Autism Spectrum Disorder in acommunity group setting[J]. BMC Pediatr, 2013, 13(1): 3.
[12] Koegel RL, Bradshaw JL, Ashbaugh K, et al. Children with autism using pivotal response treatment[J]. J Autism Dev Disord, 2014, 44(4): 816-827.
[13] Smith IM, Koegel RL, Koegel LK, et al. Effectiveness of a novel community-based early intervention model for children with autistic spectrum disorder[J]. Am J Intellect Dev Disabil, 2010, 115(6): 504-523.
[14] Ospina MB, Krebs Seida J, Clark B, et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review[J]. PLoS One, 2008, 3(11): e3755.
[15] Warren Z, Veenstra-Vander Weele J, Stone W, et al. Therapies for children with autism spectrum disorders[M]. Rockville: Agency for Healthcare Research and Quality (US), 2011.
[16] Posey DJ, Erickson CA, McDougle CJ. Developing drugs for core social and communication impairment in autism[J]. Child Adolesc Psychiatr Clin N Am, 2008, 17(4): 787-801.
[17] Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta analysis[J]. J Pediatr Health Care, 2012, 26(4): 291-299.
[18] 韦斌垣, 黄飞, 覃小田. 利培酮在治疗孤独症儿童行为问题中的作用[J]. 中国当代儿科杂志, 2011, 13(3): 216-218.
[19] Findling RL, Mankoski R, Timko K, et al. A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder[J]. J Clin Psychiatry, 2014, 75(1): 22-30.
[20] Marcus RN, Owen R, Manos G, et al. Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study[J]. J Clin Psychiatry, 2011, 72(9): 1270-1276.
[21] Mahajan R, Bernal MP, Panzer R, et al. Clinical practice pathways for evaluation and medication choice for attention-deficit/hyperactivity disorder symptoms in autism spectrum disorders[J]. Pediatrics, 2012, 130(Suppl 2): S125-S138.
[22] Bent S, Hendren RL, Zandi T, et al. Internet-based, randomized controlled trial of omega-3 fatty acids for hyperactivity in autism[J]. J Am Acad Child and Adolesc Psychiatry, 2014, 53(6): 658-666.
[23] Malow BA, Byars K, Johnson K, et al. A practice pathway for the identification, evaluation, and management of insomnia in children and adolescents with autism spectrum disorders[J].Pediatrics, 2012, 130(Suppl 2): S106-S124.
[24] Miano S, Ferri R. Epidemiology and management of insomnia in children with autistic spectrum disorders[J]. Paediatr Drugs, 2010, 12(2): 75-84.
[25] Cortesi F, Giannotti F, Sebastiani T, et al. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial[J]. J Sleep Res, 2012, 21(6): 700-709.
[26] Nakane R, Oka Y. Excitatory action of GABA in the terminal nerve gonadotropin-releasing hormone neurons[J]. Neurophysiol, 2010, 103(3): 1375-1384.
[27] Lemonnier E, Ben-Ari Y. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects[J]. Acta Paediatr, 2010, 99(12): 1885-1888.
[28] Lemonnier E, Degrez C, Phelep M, et al. A randomised controlled trial of bumetanide in the treatment of autism in children[J]. Transl Psychiatry, 2012, 2: e202.
[29] 李洪华, 贾飞勇. 口服布美他尼联合康复训练治疗儿童孤独症的初步研究[D]. 吉林大学学位论文, 2012.
[30] Modahl C, Fein D, Waterhouse L, et al. Does oxytocin deficiency mediate social deficits in autism?[J]. J Autism Dev Disord, 1992, 22(3): 449-451.
[31] Green L, Fein D, Modahl C, et al. Oxytocin and autistic disorder: alterations in peptide forms[J]. Biol Psychiatry, 2001, 50(8): 609-613.
[32] Gordon I, Vander Wyk BC, Bennett RH, et al. Oxytocin enhances brain function in children with autism[J]. Proc Natl Acad Sci USA, 2013, 110(52): 20953-20958.
[33] Andari E, Duhamel JR, Zalla T, et al. Promoting social behavior with oxytocin in high functioning autism spectrum disorders[J]. Proc Natl Acad Sci USA, 2010, 107(9): 4389-4394.
[34] Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger's disorders[J]. Neuropsychopharmacology, 2003, 28(1): 193-198.
[35] Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism[J]. Biol Psychiatry, 2007, 61(4): 498-503.
[36] Gröber U, Spitz J, Reichrath J, et al. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare[J]. Dermatoendocrinol, 2013, 5(3): 331-347.
[37] Kalueff AV, Minasyan A, Keisala T, et al. The vitamin D neuroendocrine system as a target for novel neurotropic drugs[J]. CNS Neurol Disord Drug Targets, 2006, 5(3): 363-371.
[38] Vignali DA, Collison LW, Workman CJ. How regulatory T cells work[J]. Nat Rev Immunol, 2008, 8(7): 523-532.
[39] Kocovska E, Fernell E, Billstedt E, et al. Vitamin D and autism: Clinical review[J]. Res Dev Disabil, 2012, 33(5): 1541-1550.
[40] Humblea MB, Gustafssonb S, Bejerota S. Low serum levels of 25-hydroxyvitamin D (25-OH-D) among psychiatric out-patients in Sweden: Relations with season, age, ethnic origin and psychiatric diagnosis[J]. J Steroid Biochem Mol Biol, 2010, 121(1-2): 467-470.
[41] Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity[J]. J Neuroinflammation, 2012, 9: 201.
[42] De Souza Tostes MH, Pooninin HC, Gattaz WF, et al. Low serum levels of 25-hydroxyvitamin D(25-OHD) in children with autism[J]. Trends Psychiatry Psychother, 2012, 34(3): 161-163.
[43] Neumeyer AM, Gates A, Ferrone C, et al. Bone density in peripubertal boys with autism spectrum disorders[J]. J Autism Dev Disord, 2013, 43(7): 1623-1629.
[44] Gong ZL, Luo CM, Wang L, et al. Serum 25-hydroxyvitamin D levels in Chinese children with autism spectrum disorders[J]. Neuroreport, 2014, 25(1): 23-27.
[45] Kocovska E, Andorsdottir G, Weihe P, et al. Vitamin D in the general population of young adults with autism in the faroe islands[J]. J Autism Dev Disord, 2014, 44(12): 2996-3005.
[46] 杜琳, 单玲, 王冰, 等. 孤独症谱系障碍患儿血清25(OH)D水平的检测[J]. 中国当代儿科杂志, 2015, 17(1): 68-71.
[47] Fernell E, Barnevik-Olsson M, Bagenholm G, et al. Serum levels of 25-hydroxyvitamin D in mothers of Swedish and of Somali origin who have children with and without autism[J]. Acta Paediatr, 2010, 99(5): 743-747.
[48] Grant WB, Cannell JJ. Autism prevalence in the United States with respect to solar UV-B doses: an ecological study[J]. Dermatoendocrinol, 2013, 5(1): 159-164.
[49] Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004[J]. Arch Intern Med, 2009, 169(6): 626-632.
[50] Selim ME, Al-Ayadhi LY. Possible ameliorative effect of breastfeeding and the uptake of human colostrum against coeliac disease in autistic rats[J]. World J Gastroenterol, 2013, 19(21): 3281-3290.
[51] Jia FY, Wang B, Shan L, et al. Core symptoms of autism improved after vitamin D supplementation[J]. Pediatrics, 2015, 135(1): e196-e198.
[52] Noriega DB, Savelkoul HF. Immune dysregulation in autism spectrum disorder[J]. Eur J Pediatr, 2014, 173(1): 33-43.
[53] James SJ, Melnyk S, Jernigan S, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism[J]. Am J Med Genet B Neuropsychiatr Genet, 2006, 141B(8): 947-956.
[54] Rossignol DA, Rossignol LW, James SJ, et al. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study[J]. BMC Pediatr, 2007, 7: 36.
[55] Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial[J]. BMC Pediatr, 2009, 9: 21.
[56] Rossignol DA, Bradstreet JJ, Dyke KV, et al. Hyperbaric oxygen treatment in autism spectrum disorders[J]. Med Gas Res, 2012, 2(1): 16.